International Clinical Trial: Evaluating the Safety and Effects of AMP-101 in People With DOK7 Congenital Myasthenia Syndrome

Geneva, Sept. 25 -- International Clinical Trials Registry received information related to the study (NCT07830563) titled 'Evaluating the Safety and Effects of AMP-101 in People With DOK7 Congenital Myasthenia Syndrome' on Sept. 15.

Study Type: Interventional

Study Design: Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).

Primary Sponsor: Amplo Biotechnology

Condition: Congenital Myasthenia Syndrome

Intervention: Drug: AMP-101

Recruitment Status: Not recruiting

Phase: Phase 1

Date of First Enrollment: October 1, 2026

Target Sample Size: 4

To know more, visit https://clinicaltrials.gov/study/NCT07830563

Published by HT Digital Content Services with permis...